Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Poster presentation 2008
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach
It is still going through phase 3 clinical trials, which are assessing the safety and effectiveness of retatrutide for weight loss
information about their effectiveness and how to obtain them is often incomplete, misleading, or taken out of context
Meet our experts Gary Goldenberg , MD, assistant clinical professor of dermatology at the Icahn School of Medicine at Mount Sinai and dermatologist at Mount Sinai Hospital in New York City Cindy Wassef, MD, dermatologist at Premier Health Associates in Randolph, N.J
US$ 29.72
US$ 28.02
US$ 22.79
US$ 22.30
US$ 28.77
US$ 23.54
